Neurogene INC

Neurogene announces updated positive Phase 1/2 clinical data for NGN-401 gene therapy in Rett syndrome, showing durable developmental milestone gains and a well-tolerated safety profile.

Neurogene Inc. announced the successful completion of dosing in its Embolden registrational trial for NGN-401, a gene therapy for Rett syndrome, exceeding enrollment targets.

Neurogene Inc. shareholders re-elected two directors and ratified the appointment of Deloitte & Touche LLP at the 2026 Annual Meeting.

Neurogene Inc. announced first quarter 2026 financial results, highlighting significant progress in its Embolden registrational trial for NGN-401 in Rett syndrome, with approximately 90% of participants dosed.

Neurogene Inc. announced the appointment of Christy Shafer as Chief Commercial Officer and Christine Mikail to its Board of Directors, bolstering its leadership team for the advancement of its gene therapy programs.

Neurogene Inc. announced full year 2025 financial results and significant progress in its NGN-401 gene therapy program for Rett syndrome, including 100% enrollment in its registrational trial and FDA Breakthrough Therapy designation.

Neurogene Inc. reported increased net losses for Q3 2025, while advancing its NGN-401 Rett syndrome program with positive interim clinical data and maintaining a strong cash position.

Neurogene Inc. reported increased net losses for the first half of 2025, driven by higher R&D expenses for its NGN-401 Rett syndrome program, while securing FDA alignment for its registrational trial and initiating an ATM equity offering.

Neurogene Inc. reports a net loss of $22.6 million for Q1 2025, provides updates on its NGN-401 clinical trial for Rett syndrome, and discusses its strategic direction.

Neurogene Inc. released its Q3 2024 financial results, highlighting progress in its clinical programs, including positive interim data for NGN-401, and a recent $200 million private placement.

Neurogene Inc. reports a net loss of $35.4 million for the first six months of 2024, while advancing its gene therapy programs and manufacturing capabilities.

Neurogene Inc. reported a net loss of $16.9 million for the first quarter of 2024, while advancing its gene therapy programs for Rett syndrome and CLN5 Batten disease.

Neurogene Inc. reported a widened net loss for 2025 while making significant clinical and regulatory progress with its lead gene therapy candidate, NGN-401, for Rett syndrome.

Neurogene Inc.'s 2024 10-K filing reveals a year of significant clinical advancements and financial activities, including progress in Rett syndrome treatment and a private placement closing.

Neurogene Inc.'s 10-K filing details its capital structure, ongoing clinical trials for NGN-401 and NGN-101, and its proprietary EXACT technology.

Neurogene Inc. reports insider Christine Cvijic sold shares valued at approximately $36 per share as part of a pre-arranged trading plan.

Neurogene Inc. President and CFO Christine Mikail Cvijic has sold a significant number of company shares through a pre-arranged trading plan.

Director Keith Woods refiles a Form 4 to correct an administrative CIK error regarding a previously reported stock option grant.

Director Keith Woods refiled a Form 4 to correct a CIK number error regarding a previously reported stock option grant.

Director Keith Woods filed an amendment to a Form 4 to correct a CIK number error regarding a previously reported stock option grant.

Neurogene Inc. President and CFO Christine Mikail Cvijic sold 9,600 shares of common stock via a pre-arranged 10b5-1 trading plan.

Neurogene Inc. has issued its 2026 proxy statement detailing the agenda for its upcoming virtual annual meeting of stockholders on June 3, 2026.

Neurogene Inc. has filed a definitive proxy statement with the SEC regarding its upcoming Annual General Meeting.

Neurogene Inc. is holding its 2025 Annual Meeting of Stockholders virtually on June 12, 2025, to vote on director elections, amendments to equity incentive plans, executive compensation, and auditor ratification.

Neurogene Inc. has filed a definitive proxy statement with the SEC for its upcoming 2024 Annual General Meeting.

Neurogene Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 14, 2024, to vote on the election of directors, executive compensation, and the ratification of the independent auditor.

Neurogene Inc. has filed a registration statement for the resale of 4,000,042 shares of its common stock, including shares issuable upon exercise of pre-funded warrants, by selling stockholders after a recent private placement.

Trails Edge Capital Partners, LP, along with its affiliates, has reported a 5.1% beneficial ownership stake in Neurogene Inc.'s common stock.

EcoR1 Capital, LLC and its affiliates reported a 9.9% beneficial ownership stake in Neurogene Inc. common stock, including shares and warrants, as detailed in an amended Schedule 13G filing.

Commodore Capital LP and Commodore Capital Master LP have disclosed a 3.0% beneficial ownership stake in Neurogene Inc., totaling 427,866 common shares as of June 30, 2025.

Baker Bros. Advisors and its principals have disclosed a 7.0% beneficial ownership stake in Neurogene Inc., holding nearly one million shares of common stock.

Baker Bros. Advisors LP and its affiliates have disclosed a beneficial ownership of approximately 9.95% in Neurogene Inc.'s common stock as of March 31, 2025, through a Schedule 13G filing.

FMR LLC and its affiliates, along with Abigail P. Johnson, have filed an amended Schedule 13G disclosing a passive beneficial ownership of 3.1% of Neurogene Inc.'s common stock as of March 31, 2025.